INTRODUCTION
The nuclear lamina that underlies the inner nuclear membrane (INM) is a meshwork of type-V intermediate filament proteins, consisting primarily of A-and B-type lamins (Gü ttinger et al., 2009) . Mammalian somatic cells express four major types of lamins, including A and C encoded by Lmna (Burke and Stewart, 2006; Stuurman et al., 1998) , and B1 and B2, each encoded by their own genes (Lmnb1 and 2) (Shimi et al., 2008; Stuurman et al., 1998) . In addition to providing mechanical strength to the nucleus, recent discoveries in nuclear-lamina-associated human diseases have established intimate connections between the nuclear envelope/lamina and processes such as gene expression, DNA repair, cell cycle progression, and chromatin organization (Liu et al., 2005; Nagano and Arahata, 2000; Chi et al., 2009a; Capell and Collins, 2006; Worman and Courvalin, 2004) .
Some 28 diseases/anomalies (the nuclear envelopathies) are linked to mutations in proteins of the nuclear envelope and lamina, and about half the diseases arise from mutations in the Lamin genes, predominately LMNA. These disease phenotypes range from cardiac and skeletal myopathies, lipodystrophies, and peripheral neuropathies to premature aging with early death Stewart, 2002, 2006; Burke et al., 2001; Chi et al., 2009a; Worman and Courvalin, 2004) . Two notable laminopathies are the autosomal-dominant form of Emery-Dreifuss muscular dystrophy (AD-EDMD), which results in muscle wasting and cardiomyopathy, and Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic premature aging disease in which affected individuals expire with a mean life span of 13 years (Kudlow et al., 2007) . AD-EDMD is caused by missense mutations and/or deletions throughout the LMNA gene that generally disrupt the integrity of the lamina, resulting in mechanical weakening of the nucleus and making it more vulnerable to mechanical stress. With HGPS, most cases arise from a single heterozygous mutation at codon 1824 of LMNA. This mutation produces an inframe deletion of 50 amino acids and generates a truncated form of LAD50 lamin A, termed progerin, which remains farnesylated Eriksson et al., 2003; Goldman et al., 2004) . HGPS individuals are overtly normal at birth, with the disease manifesting around 18 months (Merideth et al., 2008) . The current view is that the permanently farnesylated progerin is affixed to the nuclear membrane and results in a toxic gain of function that elicits HGPS. How farnesylated progerin triggers HGPS is not understood. Lmna À/À mice (Sullivan et al., 1999) were developed and found to model AD-EDMD. Subsequently, another mouse model was created with homozygous Lmna L530P/L530P mutations in Lmna (later termed LmnaD9 mice; Hernandez et al., 2010; Mounkes et al., 2003) that expresses a deleted form of Lmna (deleted for exon 9 with the inframe removal of 40 amino acids of lamin A/C). There are distinct differences between Lmna À/À , LmnaD9, and HGPS. The Lmna À/À mouse does not express a full-length lamin A protein, whereas the LmnaD9 mouse recapitulates many HGPS-associated pathologies including early death, skeletal anomalies, and vascular smooth muscle defects (Mounkes et al., 2003) and homozygously expresses a farnesylated lamin A-DExon9 mutant protein that, though similar, is not identical to the heterozygous expression of the LAD50 mutant protein in HGPS. Nonetheless, Lmna À/À and LmnaD9 mice and HGPS individuals share three significant features. All have Lmna mutations, significant dystrophic cellular, tissue and organ changes, and markedly abbreviated life spans. Currently, although aberrant LAD50 progerin expression is implicated as causing HGPS, the full understanding of this and other causal events for lamin A-associated pathology is elusive. The lamins are proposed to interact with many INM proteins, including Emerin, lamina-associated polypeptides (LAPs) and MAN1, and the SUN domain proteins, SUN1 and SUN2 (Burke and Stewart, 2002; Mattioli et al., 2011; Crisp et al., 2006; Ostlund et al., 2009) . A detailed biochemical understanding of these interactions is complicated by the relative insolubility of these proteins. The SUNs are components of the LINC (links the nucleoskeleton and cytoskeleton) complex that connect the nuclear lamina and envelope with the cytoskeleton (Crisp et al., 2006) . The LINC complex is important in nuclear positioning and cellular migration in lower and higher eukaryotes (Malone et al., 1999) . How the inner nuclear membrane SUN proteins function with lamins remains unclear, but currently there is no evidence that they are involved in laminopathies (Haque et al., 2010) . Here we present evidence that Lmna À/À , LmnaD9, and HGPS dysfunctions converge at a common pathogenic overaccumulation of the inner nuclear envelope Sun1 protein. Accordingly, loss of the Sun1 gene in Lmna À/À and LmnaD9 mice extensively rescues cellular, tissue, organ, and life span abnormalities. Similarly, the knockdown of overaccumulated SUN1 protein in primary HGPS cells corrected their nuclear defects and cellular senescence. Our results reveal Sun1 overaccumulation as a potentially pivotal pathologic effector of some laminopathies.
RESULTS

Loss of Sun1
Ameliorates Lmna À/À and LmnaD9
Pathologies
To gain insight into the cooperativity, if any, between INM proteins and the underlying lamina in disease development, we bred Sun1 +/À (Chi et al., 2009b) and Lmna +/À (Sullivan et al., 1999) Sun1, rather than exacerbating pathology, unexpectedly ameliorated deficits in body weight ( Figure 1A ; p < 0.0001) and longevity ( Figure 1B ; p < 0.01). This rescue of Lmna À/À mice by loss of Sun1 was verified in a second laminopathy model, the LmnaD9 mutant mouse (Mounkes et al., 2003; Hernandez et al., 2010) . The body weight and longevity deficits in LmnaD9 mice were also rescued in the LmnaD9Sun1 À/À counterparts ( Figures 1C   and 1D ). Remarkably, whereas all LmnaD9 mice expired by 30 days after birth, their LmnaD9Sun1 À/À littermates thrived past this date, and most achieved life spans more than twice this duration ( Figure 1D To seek a molecular explanation for loss-of-lamin A changes and their correction by Sun1 depletion, we investigated Sun1 expression in lamin A WT and Lmna À/À mouse embryonic fibroblasts (MEFs). Sun1 and lamin A colocalize at the Nuclear Envelope (NE) in WT MEFs ( Figure 3A , left panels). In contrast, in Lmna
MEFs, Sun1 is found in the NE and at increased levels in the Golgi ( Figure 3A , middle panels; Figure S2A ) based on costaining with Golgi marker GM130 ( Figure S2A , right), but not with ER marker calnexin ( Figure S2A , left). NE localization and Golgi overaccumulation of Sun1 were also seen in LmnaD9 mouse fibroblasts ( Figure S2A , right). That Sun1 localizes with Golgi constituents in Lmna À/À cells was supported by biochemical fractionation of mouse tissues that detected Sun1 and GM130 in the same sucrose density fractions ( Figure S2B ). When Lmna À/À cells were examined for the relative distribution of Sun1 in the NE versus the Golgi, the amount in the latter increased proportionally with its level in the former ( Figure S2C) whereas Emerin and Nesprin1 were not significantly increased but showed modest increases in ER relocalization (Figures S2D and S2E) . The increase in Sun1 protein ( Figure S2E ) was not due to elevated Sun1 mRNA levels (compare WT and Lmna À/À ; Figure S2F ). This result, together with heightened 
Sun1
À/À MEFs without significantly affecting WT MEFs ( Figure 3E ). The transfections also elicited dose-dependent increases in the apoptosis of Lmna Figure 3F ).
Golgi Targeting of Sun1 Elicits Nuclear Herniations
A remarkable feature of Sun1 expression in Lmna À/À MEFs is its misaccumulation in the extranuclear Golgi apparatus ( Figure 3A and Figure S2A ). Protein misaccumulation in human organelle storage disorders has been described for lysosomal storage diseases such as Fabry, Tay-Sachs, Gaucher, Niemann-Pick, Pompe, and Krabbe (Metz et al., 2011) and for endoplasmic reticulum storage diseases such as cystic fibrosis, a1-antitrypsin deficiency, hereditary hypoparathyroidism, and procollagen type I, II, and IV deficiency (Rutishauser and Spiess, 2002) ; however, to date, there are no good examples of Golgi storage diseases. To test whether the deliberate Golgi misaccumulation of Sun1 is significantly pathogenic, we constructed an HAtagged Tgn38-fused Golgi-targeting mSun1 expression vector (Tgn38 is an integral Golgi protein; see Szentpetery et al. [2010] ). Sun1 protein, when overexpressed in WT MEFs, localized to the nuclear envelope and elicited barely discernable mild nuclear blebbings ( Figure 4A ), whereas transfected Tgn38-Golgi-targeted mSun1 dramatically increased Golgi accumulation and nuclear herniations with obvious cytoplasmic accumulation of lamin B1 ( Figure 4B ) in 83% of Tgn38-GolgimSun1 expressing cells ( Figure 4C ). Recently, it was reported that the Sun1-related Sun2 protein has a Golgi retrieval signal, ensuring its transport from the Golgi back to the ER (Turgay et al., 2010) .
Although not yet determined, Sun1 may differ in the Golgi retrieval signal, which could explain why a SUN1 mutant (human SUN1 [aa] 103-785) ( Figure S4 ; Haque et al., 2010; Chi et al., 2007) and a wild-type Sun1 protein that is expressed in the absence of cell endogenous lamin A (i.e., Lmna À/À cells; Figures 3A and S2A) are both found in the Golgi. We also checked whether the Golgi-localizing SUN1 (103-785) mutant elicits nuclear aberrations. Indeed, overexpression of the SUN1 (103-785) mutant increased nuclear envelope rupture and cytoplasmic redistribution of lamin B1 ( Figure S4) .
The above results suggest that reducing Sun1 accumulation in the Golgi might moderate Lmna À/À nuclear irregularities. Brefeldin A (BFA) is an antibiotic that reversibly interferes with the anterograde transport of macromolecules from the endoplasmic reticulum (ER) to the Golgi (Marie et al., 2008 BFA at 10 mg/ml for 24 hr showed a reduction in most, albeit not all, Golgi-trafficked Sun1 and GM130 proteins ( Figure 5A , left) with statistically significant (p < 0.001; p < 0.01) reduction in nuclear aberrations in cells passaged four (P4) to eight (P8) times in culture ( Figure 5A , right graph). We also treated Lmna À/À MEFs with nocodazole to block microtubule organization ( Figure 5B ) or latrunculin B to interrupt actin assembly ( Figure 5C ). Nocodazole disrupts the Golgi apparatus (Thyberg and Moskalewski, 1999), and its treatment of Lmna À/À MEFs led to a punctated redistribution of otherwise Golgiassociated Sun1 and GM130 ( Figure 5B ). This treatment also led to a moderate, but statistically significant, reduction of nuclear aberrations ( Figure 5B , right graph). In contrast, latrunculin B did not affect Sun1 distribution in the Golgi or ameliorate nuclear defects (Figure 5C ). Collectively, the findings demonstrate that endogenous ( Figure 5 ) or exogenous ( Figures 4 and S4) Sun1 misaccumulation in the Golgi elicits substantial cellular pathologies, and that reducing Sun1 Golgi accumulation restores cellular normalcy.
SUN1 Overaccumulation in HGPS Cells Correlates with Dysfunction
We next investigated SUN1 expression in HGPS cells, querying whether (and how) this protein might contribute to pathology. We immunostained SUN1 expression in human skin fibroblasts from seven independent HGPS (LMNA c.1824C>T [G608G]) ( Figure S5A and Table  S1 ) and four normal individuals and verified LAD50 progerin expression (Goldman et al., 2004) in HGPS, but not in normal, cells (Figure S5B ). By immunofluorescence, brighter SUN1 staining was observed in HGPS cells compared to control cells (representative examples are in Figure 6A and Figure S5A ; normal versus HGPS), which is consistent with increased SUN1 expression by western blotting ( Figure S5B ) and with an earlier report of SUN1 accumulation in HGPS cells (Haque et al., 2010) . Of note, our stainings showed that not every HGPS cell had elevated SUN1, but that cells that stained brightest for SUN1 were also ones that had larger nuclei and more severe nuclear morphological distortions (compare dim-SUN1 HGPS cells, white arrowheads to bright-SUN1 HGPS cells, yellow arrowheads; Figure 6A ). SUN1 mRNA levels did not differ significantly in HGPS versus normal cells ( Figure S5C ), supporting the interpretation that reduced protein turnover ( Figure S3B) , not increased transcription, underlies SUN1 accumulation.
To address whether elevated SUN1 levels in HGPS result in pathologies, we asked whether knocking down SUN1 alleviates nuclear defects. SUN1-specific or control siRNAs were transfected into HGPS or normal skin fibroblasts, and nuclear appearance was monitored ( Figure S5D ). The nuclear morphologies were unchanged in cells treated with control siRNA (Figures 6B  and S5E ), but SUN1-specific siRNA reduced the prevalence of bright-SUN1 HGPS cells (compare AG11498 upper to lower row, Figures 6B and 6C ) and lowered the number of cells with aberrant nuclei (Figures 6B, 6D , and S5E; Table S1 ). The contribution of SUN1 to nuclear morphology was assessed conversely by deliberately overexpressing exogenous SUN1. Ectopic SUN1 overexpression in HGPS and normal fibroblasts significantly increased aberrant nuclei ( Figure 6E ).
SUN1 Expression Correlates with HGPS Heterochromatin Profile and Cellular Senescence
Chromatin disorganization and massive heterochromatin loss are correlated with nuclear shape alterations in HGPS cells (Shumaker et al., 2006; Goldman et al., 2004) . Assays for HGPS heterochromatin loss have included markers such as the lamin A-associated NURD (nucleosome remodeling and deacetylase) component RBBP4 (Pegoraro et al., 2009 ) and the pan heterochromatin marker histone H3K9me3 (Shumaker et al., 2006; Scaffidi and Misteli, 2005) . To corroborate the nuclear morphology findings (Figure 6 ), we investigated how SUN1 expression correlates with previously described HGPS heterochromatin changes. When HGPS or normal-skin fibroblasts were stained for RBBP4 ( Figure 7A , left) or H3K9me3 ( Figure 7A , right), an inverse correlation was observed between the expression of SUN1 and RBBP4 ( Figure 7B , left) or H3K9me3 ( Figure 7B , right). In agreement with the results in Figure 6A , only a subset of HGPS cells was bright SUN1 (yellow arrows = bright-SUN1, white arrows = dim-SUN1; Figure 7A) ; interestingly, the bright-SUN1 cells were also those with the larger, more distorted nuclei as well as sparse staining for RBBP4 ( Figures 7A and 7B , left) or H3K9me3 (Figures 7A and 7B, right) . Separately, we found that RBBP4 expression was substantially reduced in $70% of Lmna À/À MEFs ( Figure S6A ) and in Lmna À/À mouse liver tissue ( Figure S6B ), further supporting an inverse relationship between Sun1 and NURD activity. We next asked whether knockdown of SUN1 would reverse HGPS-associated heterochromatin changes. We compared control-RNAi and SUN1-RNAi transfected HGPS cells and found that the latter did recover RBBP4 expression relative to the former ( Figure 7C ). Because heterochromatin dysregulation is correlated with cellular senescence (Di Micco et al., 2011) and because HGPS cells senesce prematurely (DeBusk, 1972; Eriksson et al., 2003) , we queried how SUN1 affects HGPS senescence by knocking down SUN1 for 96 hr and examining acidic senescence-associated b-galactosidase (SA-b-Gal) in control and HGPS cells ( Figure 7D) . In normal cells, the extent of senescence was similar ($9%) between control-siRNA and SUN1-siRNA samples ( Figure 7D) ; however, in HGPS cells, the observed high level of ambient senescence ($22%), as measured by b-galactosidase, was dramatically decreased (to $6%) after SUN1 knockdown. Moreover, HGPS fibroblasts, when treated with SUN1-RNAi, gained a proliferative advantage over control-RNAi treated cells ( Figure 7E ). These data collectively support the interpretation that increasing SUN1 accumulation is associated with HGPS pathology and removing overexpressed SUN1 and restores normal cellular physiology.
DISCUSSION
Here, we show that aberrant Sun1 expression is a critical pathogenic event common to Lmna À/À , LmnaD9, and HGPS disorders. As noted here and elsewhere, Lmna À/À mice (Sullivan et al., 1999) , LmnaD9 mice (Hernandez et al., 2010; Mounkes et al., 2003) , and HGPS individuals (Merideth et al., 2008) share a constellation of disorders that include nuclear aberrations, dystrophic organ and tissue abnormalities, and abbreviated life spans. A current view is that progerin is causal of the LAD50 HGPS disease (Burtner and Kennedy, 2010; Liu et al., 2005; Scaffidi and Misteli, 2005; Goldman et al., 2004) . How progerin mechanistically signals cellular and tissue damage remains elusive. That said, the existence of the dystrophic and cardiomyopathic pathologies in Lmna À/À mice and multiple examples of Lmna mutations (Novelli et al., 2002; Plasilova et al., 2004; Sullivan et al., 1999 ) that do not synthesize progerin but do produce degenerative-dystrophic diseases such as Emery-Dreifuss muscular dystrophy (Bonne et al., 1999) , Charcot- MarieTooth (De Sandre-Giovannoli et al., 2002; Chaouch et al., 2003) , Mandibuloacral dysplasia (Novelli et al., 2002) , Dunnigan-type familial partial lipdystrophy (Cao and Hegele, 2000) , atypical Werner's syndrome (Chen et al., 2003) , and limb girdle muscular dystrophy (Muchir et al., 2000; Kitaguchi et al., 2001) , require an understanding of progerin-independent and dependent factors/cofactors underlying the pathologies. The Sun1 protein connects the nucleoplasm with the cytoskeleton (Crisp et al., 2006) and has roles in nuclear anchorage, nuclear migration, and cell polarity. Deficits in Sun1 correlate with developmental retardation in neurogenesis, gametogenesis, myogenesis, and retinogenesis (Ding et al., 2007; Lei et al., 2009; Zhang et al., 2009; Yu et al., 2011; Chi et al., 2009b) . To date, how an inner nuclear envelope protein like Sun1 fits into the pathogenesis of laminopathies is unknown (Stewart et al., 2007) .
The major unexpected finding here is that whereas Lmna À/À mice and LmnaD9 mice thrive poorly and die prematurely, the removal of Sun1, creating Lmna
LmnaD9Sun1
À/À mice, rescued pathologies and dramatically improved longevity (Figures 1 and 2 ). To better understand these results, we observed that at the cellular level, Lmna À/À and LmnaD9 fibroblasts have uniformly increased Sun1 expression with significant protein misaccumulation in the Golgi ( Figure 3A and Figure S2 ). Furthermore, approximately one in three LAD50 HGPS fibroblasts (Figures 6, 7, and S5; Table S1 ) was elevated for SUN1 expression with the bright (high)-SUN1, but not the dim (low)-SUN1, cells, exhibiting abnormal nuclear size and shape, heterochromatin RBBP4 and H3K9me3 markers, and cellular senescence (Figures 6 and 7) . Even though one cannot do a SUN1 knockout experiment in LAD50 HGPS individuals, the knockdown of SUN1 in LAD50 HGPS cells considerably improved nuclear size and/or shape defects, heterochromatin loss, and cellular senescence (Figures 6 and 7) . Thus, although the approaches (knockout and knockdown) and disease models (Lmna À/À , LmnaD9, and LAD50 HGPS) are not identical, a parsimonious interpretation consistent with the collective results is that Sun1 overaccumulation represents a common effector of Lmna positioned by mechanisms that are still obscure but may depend on interaction with lamin A filaments underlying the nuclear matrix (Haque et al., 2006; Mattioli et al., 2011; Ostlund et al., 2009 ). As noted above, a SUN1 protein deleted in its N-terminal ($100 amino acids) lamin A-interacting domain relocates from the NE to the Golgi ( Figure S4 ; Haque et al., 2010; Chi et al., 2007) . Emerging evidence suggests that the SUN1-related SUN2 protein has a Golgi retrieval sequence (Turgay et al., 2010) that is required for retrieval of SUN2 from the Golgi to the ER. Differences between the two proteins may explain why Sun1, but not Sun2, expressed in the absence of cell endogenous lamin A (i.e., Lmna À/À cells; Figure 3 and Figure S2 ), accumulates in the Golgi. Our findings show that Sun1 accumulation arises from reduced protein turnover ( Figure S3 ) and not increased transcription ( Figures S2F and S5C ), suggesting that approaches to enhance protein degradation might be therapeutically beneficial (Cao et al., 2011) . We did not discern obvious Golgi overaccumulation of endogenous SUN1 in LAD50 HGPS cells. Although the explanation for this remains unclear, it could be that Golgi overaccumulation of SUN1 in human cells is highly toxic and selects rapidly against the viability of cultured HGPS cells, or that the heterozygous expression of wild-type lamin A in LAD50 HGPS cells is sufficient to locate endogenous SUN1 to the NE, preventing overt Golgi misaccumulation. Relevant to the former explanation, we observed that early-passage Lmna À/À MEFs show more dramatic Sun1-Golgi misaccumulation than late-passage counterparts, consistent with selection against cells with high Sun1-Golgi misaccumulation. What might be the consequences of Sun1 mislocation in the Golgi? Our Golgi-targeting experiments with mSun1-Tgn38 ( Figure 4 ) and SUN1 (103-785) mutant protein ( Figure S4 ) showed that Golgi storage of Sun1 is cytotoxic. This toxicity may be akin to that elicited in abnormal human lysosomal (Metz et al., 2011) or ER storage (Rutishauser and Spiess, 2002) diseases. Aside from organelle storage disorders, other types of protein aggregation maladies like Alzheimer's (Gouras et al., 2010) exist. In Alzheimer's disease, evidence now suggests that it is the small, soluble amyloid-b oligomers, not the large, easily visualized amyloid-b fibrils/plaques, that produce neurotoxicity (Crews and Masliah, 2010) . As mentioned above, we currently do not exclude that Golgi accumulation of SUN1 may indeed occur in LAD50 HGPS cells in vivo and that such cells may have rapidly succumbed and therefore are not represented in the mostly late-passage repository-deposited HGPS fibroblasts (Table S1 ). However, like soluble amyloid-b oligomers, which need not present as gross aggregates to be cytotoxic, it may be that the degree of SUN1 overexpression in LAD50 HGPS cells ( Figure 6E ) is sufficient to functionally trigger pathology without having to reach levels required for overt Golgi spillage. In LAD50 HGPS cells, increased SUN1 accumulation in the nuclear envelope may sufficiently create dysfunction by rendering a more rigid meshwork.
Progerin underlies LAD50 HGPS disease development (Eriksson et al., 2003; Scaffidi and Misteli, 2005; Goldman et al., 2004) . How does SUN1 fit into the picture where progerin synthesis is the initial event inciting cellular dysfunction? In primary LAD50 HGPS cells or LmnaD9 mice where progerin ( Figure S5B ) or lamin A-DExon9 protein is expressed, Sun1 knockdown is sufficient to remedy cellular aberrancies and also senescence and longevity defects (Figures 1, 6, and 7) . A cogent interpretation of these results is that SUN1 accumulation is positioned downstream of progerin or lamin A-DExon9, such that the depletion of SUN1 sufficiently interrupts pathologic signaling. In Lmna À/À mice, in which no progerin protein is synthesized, our data show that Sun1 accumulation remains an important trigger of loss-of-lamin A pathology. Future experiments are needed to clarify, in noncodon 1824 (i.e., non LAD50) forms of HGPS (Plasilova et al., 2004) and in the many rare dystrophic human diseases (Burke et al., 2001; Chi et al., 2009a; Capell and Collins, 2006; Kudlow et al., 2007) where no gain-of-function progerinlike protein is synthesized, whether SUN1 (or other nuclear envelope protein) misaccumulation is similarly important to pathogenesis. Our current findings do suggest that at least in the Lmna À/À , LmnaD9, and LAD50 HGPS diseases, Sun1 overaccumulation is critical to pathologies. If this notion can be broadly applied, it suggests that future clinical trials and therapies for laminopathies that treat disease upstream events (i.e., targeting progerin) without resolving the downstream pathogenic events (i.e., Sun1 misaccumulation) may be ineffective.
EXPERIMENTAL PROCEDURES Animals
Knockout mice were created using standard procedures. Because Sun1
and Lmna À/À mice are reproductively defective (Ding et al., 2007; Alsheimer et al., 2004; Chi et al., 2009b) (Mounkes et al., 2003) to generate LmnaD9Sun1 À/À mice.
Lmna mutant lines are available from Jax Labs and LmnaD9 mice from C.L. Stewart. Mouse genotypes were verified by PCR. All animal experiments were conducted according to animal study protocols approved by the National Institutes of Health (NIH) or the Singapore Animal Use Committee.
Immunofluorescence and Confocal Microscopy Cells, fixed in 4% paraformaldehyde in PBS for 30 min and permeabilized with 0.1% Triton X-100 for 5 min at room temperatures, were incubated with 1% BSA in PBS for 30 min to block nonspecific binding. Antibodies were diluted at 1:100 to 1:1,000 and incubated for 1.5 hr at room temperature. After three washes with PBS, cells were probed with fluorescent (Alexa-488, Alexa-594, or Alexa-647)-conjugated secondary antibodies. Nuclei were counterstained with Hoechst33342 or DAPI (Invitrogen), and Sun1 intensity was visualized (D) Visualization (left) and quantification (right) of acidic senescence associated b-galactosidase (SA-b-Gal) in normal (AG03257) and HGPS (AG11498 at passage 8) fibroblasts transfected with control or SUN1 RNAi for 96 hr. Standard deviations are from three independent assays counting 1200 to 2000 cells in each experiment. Cell scoring was performed in a blinded fashion by an independent investigator. P value (Chi-square) is indicated.
(E) Cell proliferation in normal (AG03257) and HGPS (AG11498) cells transfected with control or SUN1 RNAi. Cells at $50% confluency were transfected. When cells reached confluency, equal numbers were seeded into dishes and quantified for proliferation using Cell Counting Kit-8 24 hr after cell seeding (day 0) and after another 4, 
